Published in Front Oncol on June 04, 2014
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Harnessing oncolytic virus-mediated anti-tumor immunity. Front Oncol (2014) 0.75
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 2.72
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
TAP-independent, beta 2-microglobulin-dependent surface expression of functional mouse CD1.1. J Exp Med (1995) 1.96
Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol (1998) 1.62
Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther (2009) 1.54
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther (2009) 1.30
The CD1 system. Tissue Antigens (1991) 1.16
Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev (2010) 1.13
Vesicular stomatitis virus matrix protein impairs CD1d-mediated antigen presentation through activation of the p38 MAPK pathway. J Virol (2008) 0.99
Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. J Immunol (2013) 0.89
Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy. J Virol (2011) 0.87
The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control. Mol Ther (2014) 0.85